Anika Completes Divestiture of Parcus Medical
Anika Therapeutics (NASDAQ: ANIK) has completed the divestiture of its Parcus Medical business to Medacta Group SA on March 7, 2025. The transaction was completed with total cash consideration received at closing, subject to customary post-closing adjustments.
This strategic move aligns with Anika's previously announced strategic review, allowing the company to sharpen its focus on its core hyaluronic acid technology and advance its Regenerative Solutions portfolio in early intervention orthopedics.
Both companies have committed to ensuring a smooth transition for employees, distributor agents, surgeon customers, and patients. Goodwin Procter served as legal counsel and Piper Sandler acted as exclusive financial advisor to Anika for the transaction.
Anika Therapeutics (NASDAQ: ANIK) ha completato la cessione della sua attività Parcus Medical al Medacta Group SA il 7 marzo 2025. La transazione è stata conclusa con un corrispettivo in contante totale ricevuto al momento della chiusura, soggetto a consuete regolazioni post-chiusura.
Questa mossa strategica è in linea con la revisione strategica precedentemente annunciata da Anika, consentendo all'azienda di concentrare meglio i propri sforzi sulla sua tecnologia acido ialuronico e di avanzare nel suo portafoglio di Soluzioni Rigenerative nell'ortopedia di intervento precoce.
Entrambe le aziende si sono impegnate a garantire una transizione fluida per i dipendenti, gli agenti distributori, i chirurghi clienti e i pazienti. Goodwin Procter ha svolto il ruolo di consulente legale e Piper Sandler ha agito come consulente finanziario esclusivo per Anika per la transazione.
Anika Therapeutics (NASDAQ: ANIK) ha completado la venta de su negocio Parcus Medical al Medacta Group SA el 7 de marzo de 2025. La transacción se cerró con un pago en efectivo total recibido al cierre, sujeto a ajustes post-cierre habituales.
Este movimiento estratégico se alinea con la revisión estratégica previamente anunciada por Anika, permitiendo a la empresa enfocar mejor sus esfuerzos en su tecnología de ácido hialurónico y avanzar en su portafolio de Soluciones Regenerativas en ortopedia de intervención temprana.
Ambas empresas se han comprometido a asegurar una transición fluida para empleados, agentes distribuidores, cirujanos clientes y pacientes. Goodwin Procter actuó como asesor legal y Piper Sandler como asesor financiero exclusivo de Anika para la transacción.
아니카 테라퓨틱스 (NASDAQ: ANIK)는 2025년 3월 7일 메닥타 그룹 SA에 파커스 메디컬 사업부의 매각을 완료했습니다. 거래는 종료 시 총 현금 대가를 수령하는 것으로 완료되었으며, 일반적인 종료 후 조정이 적용됩니다.
이 전략적 결정은 아니카가 이전에 발표한 전략 검토와 일치하며, 회사가 히알루론산 기술에 집중하고 조기 개입 정형외과 분야에서 재생 솔루션 포트폴리오를 발전시킬 수 있도록 합니다.
양사는 직원, 유통 대리인, 외과 의사 고객 및 환자를 위한 원활한 전환을 보장하기 위해 최선을 다하고 있습니다. 굿윈 프로터는 법률 자문 역할을 했고, 파이퍼 샌들러는 거래에 대해 아니카의 독점 재정 자문 역할을 했습니다.
Anika Therapeutics (NASDAQ: ANIK) a finalisé la cession de son activité Parcus Medical au Medacta Group SA le 7 mars 2025. La transaction a été conclue avec un paiement total en espèces reçu à la clôture, sous réserve des ajustements d'usage après clôture.
Ce mouvement stratégique s'aligne avec la révision stratégique précédemment annoncée par Anika, permettant à l'entreprise de se concentrer davantage sur sa technologie acide hyaluronique et de faire avancer son portefeuille de Solutions Régénératives dans le domaine de l'orthopédie d'intervention précoce.
Les deux entreprises se sont engagées à garantir une transition fluide pour les employés, les agents distributeurs, les chirurgiens clients et les patients. Goodwin Procter a agi en tant que conseiller juridique et Piper Sandler en tant que conseiller financier exclusif d'Anika pour la transaction.
Anika Therapeutics (NASDAQ: ANIK) hat am 7. März 2025 die Veräußerung ihres Parcus Medical Geschäfts an die Medacta Group SA abgeschlossen. Die Transaktion wurde mit einem Gesamtbetrag in bar zum Zeitpunkt des Abschlusses abgeschlossen, vorbehaltlich üblicher nachträglicher Anpassungen.
Dieser strategische Schritt steht im Einklang mit der zuvor angekündigten strategischen Überprüfung von Anika, die es dem Unternehmen ermöglicht, sich stärker auf seine Kerntechnologie Hyaluronsäure zu konzentrieren und sein Portfolio an regenerativen Lösungen in der frühen orthopädischen Intervention voranzutreiben.
Beide Unternehmen haben sich verpflichtet, einen reibungslosen Übergang für Mitarbeiter, Vertriebsagenten, Chirurgen und Patienten zu gewährleisten. Goodwin Procter fungierte als Rechtsberater und Piper Sandler als exklusiver Finanzberater von Anika für die Transaktion.
- Strategic focus enhancement on core hyaluronic acid technology
- Immediate cash infusion from sale completion
- Streamlined business operations
- Reduction in business diversification
- Loss of Parcus Medical revenue stream
Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio
BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced the completion of the previously announced planned divestiture of its Parcus Medical business.
Management Commentary
“The sale of Parcus marks a critical step forward as we achieve the goals of our previously announced strategic review. We are better positioned than ever to fully focus on our core hyaluronic acid technology and advance our differentiated and growing Regenerative Solutions portfolio.” said Cheryl R. Blanchard, Ph.D., President and Chief Executive Officer of Anika Therapeutics.
Parcus Medical Sale Completed
The sale of Parcus Medical to Medacta Group SA closed today, March 7, 2025 for an undisclosed amount. The sale was completed with total cash consideration received at closing, subject to customary post-closing adjustments. Anika and Medacta have agreed to work together to ensure a smooth post-close transition of the business for employees, distributor agents, surgeon customers and the patients they serve.
Advisors
Goodwin Procter served as legal counsel and Piper Sandler acted as exclusive financial advisor to Anika with respect to the sale of Parcus Medical.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on early intervention orthopedics. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
Forward-Looking Statements
This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company's expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact, including statements in Dr. Blanchard’s quote regarding our ability to advance our differentiated and growing Regenerative Solutions portfolio and our core hyaluronic acid (HA) technology. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties, and other factors. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company's research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company's ability to provide an adequate and timely supply of its products to its customers; and (x) the Company's ability to achieve its growth targets. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
When did Anika Therapeutics (ANIK) complete the sale of Parcus Medical?
What is the value of ANIK's Parcus Medical divestiture?
How does the Parcus Medical sale align with ANIK's strategic goals?
Who were the advisors for ANIK's Parcus Medical sale?
